跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Uptravi - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Uptravi
Approved
STANDARD
Uptravi
Excella GmbH & Co. KG
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
d83396c0bc6e943c
Company
Excella GmbH & Co. KG
Type
Standard
Approval Details
Approval Id
d83396c0bc6e943c
Drug Approval Philippines Name
Uptravi
Product Name
Uptravi
Registration Number
DR-XY47394
Brand Name
Uptravi
Generic Name
Selexipag
Dosage Form
Film-Coated Tablet
Dosage Strength
1.2 mg
Manufacturer
Excella GmbH & Co. KG
Importer
Johnson & Johnson (Philippines), Inc.
Company Detail Path
/organization/excella-gmbh-and-co-kg
Issuance Date
14 May 2025
Expiry Date
20 September 2029
Pharmacologic Category
Antithrombotic Agent
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
d83396c0bc6e943c
Type
Standard
Back to Philippines FDA Approvals